This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Fennec Pharmaceuticals Inc.
Drug Names(s): ADH-1
Description: Exherin is an N-cadherin antagonist. It belongs to a novel group of drugs called vascular targeting agents (VTA), or angiolytic drugs, that selectively targets tumor vasculature. In animal studies, it has been shown to cause leakage of blood from tumor vessels and ultimately death of tumor cells.
Adherex and GSK
In July 2005, GSK obtained an exlusive, worldwide option to license Exherin. If GSK were to exercise the ADH-1 option and negotiate a license agreement with Adherex, Adherex would receive upfront, development and sales milestone payments of up to approximately US$100 million in aggregate, plus double-digit royalties.
In Ocotber 2006, Adherex announced that the GlaxoSmithKline (GSK) one-time option to license ADH-1 has expired unexercised. As a result, Adherex has regained all rights relating to ADH-1 and will continue with the clinical development of the compound.
In September 2014, Adherex Technologies Inc. announced that it filed a Notice of Alteration with the British Columbia Registrar of Companies changing the name of the Company from Adherex Technologies Inc. to Fennec Pharmaceuticals Inc.
Additional information available to subscribers only: